LONDON, April 25,
2024 /PRNewswire/ -- Virax Biolabs Group Limited
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, announced today the launch of
ImmuneSelect ("ImmuneSelect") within the ViraxImmune™ T-Cell
diagnostic platform for research-use-only ("RUO"), at the European
Society of Clinical Microbiology and Infectious Diseases Global
2024 (ESCMID) Congress, which is taking place from April 27th to April 30th, 2024, in Barcelona, Spain. The Company is hosting at
Booth F43, and management will be available for discussions with
research organizations and potential partners.
"We are very pleased to launch ImmuneSelect, an important
portfolio of immune profiling solutions within our
ViraxImmune™ T-Cell diagnostic platform," commented Mr.
James Foster, Chief Executive
Officer of Virax Biolabs. "The launch marks a significant
milestone for Virax as it brings us a step closer to
commercializing ViraxImmune™ as a full In-Vitro-Diagnostic
product."
ImmuneSelect is the Company's new portfolio of immune profiling
solutions dedicated to investigating adaptive immunity.
ImmuneSelect is developed to evaluate T-Cell driven immunity and to
aid in the understanding and early characterization of symptoms
associated with post-viral syndromes, including Long COVID.
Products within the ImmuneSelect brand are for research and
investigational use only and are not intended to be used as a
diagnostics tool. The ImmuneSelect portfolio includes peptide pools
covering epitopes from pathogens linked to post-viral syndromes.
These include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 ("CD8"), Lyme
Disease, Cytomegalovirus ("CMV"), Respiratory Syncytial Virus
("RSV") and Epstein-Barr Virus ("EBV"). ImmuneSelect's
Recombinant Antibodies target cytokines and biomarkers, and they
are available in different versions unconjugated to be tested on a
range of applications including Flow Cytometry, ELISA and
ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is
compatible with most standard laboratory equipment.
Dr. Nigel McCracken, Ph.D., the
Chief Operations Officer of Virax Biolabs said, "We believe
there is great potential to utilize T-Cell diagnostics to help
detect underlying post-viral infections by initially measuring the
body's adaptive immune resistance to infections and then monitoring
the potential progression of an individual's T-Cell functions
following chronic antigen stimulation."
About Post-Viral Syndromes
Post-viral syndromes are a wide range of complex conditions
involving physical, cognitive, emotional, and neurological
difficulties that vary in severity over time. These conditions
frequently lead to a sense of tiredness and weakness, pain,
difficulty concentrating and headaches that linger after the viral
infection has cleared. Various microbial and viral infections have
been identified as possible triggers for post-viral syndromes,
including SARS-COV-2, Epstein-Barr Virus, Cytomegalovirus, Human
Herpesvirus, Enteroviruses, HPV and Zika, among others. Long
COVID represents a significant public health challenge in the
post-COVID-19 era with around 10% of SARS-COV-2 infections leading
to Long COVID with over 60 million people around the world
suffering from ongoing symptoms.
The exact underlying reason why people suffer from post-viral
syndromes is not fully understood, however several factors are
believed to play a role. These factors include problems with the
immune system, such as ongoing chronic inflammation, autoimmunity,
improper functioning of T-Cells and sometimes the reactivation of
viruses that were previously dormant in the body. Currently, there
are no reliable diagnostics for the early detection of post-viral
syndromes, including Long COVID.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of post-viral syndromes such as Long COVID and other
chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This
press release contains forward-looking statements. In addition,
from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March
31, 2023. Although we believe the expectations reflected in
such forward-looking statements are reasonable, we can give no
assurance that such expectations will prove to be correct. We are
not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-launches-portfolio-of-immune-profiling-solutions-evaluating-adaptive-immunity-in-post-viral-syndromes-at-escmid-global-2024-302125825.html
SOURCE Virax Biolabs